Date: 07-11-2026

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex,
Bandra East, Mumbai-400051
Scrip Code: MUKKA

BSE Limited
Listing Department
Dalal Street,
Mumbai-400001
Scrip Code: 544135

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on 7th November 2026.

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), this is to inform you that the Board of Directors of the Company ("Board") at their meeting held today i.e. Saturday, 7th November 2026, have *inter-alia* considered and approved the following business:

1. **Financial Results:** The unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended 30th September 2026 is enclosed. Further, the Limited Review Report received from the Statutory Auditors of the Company is also enclosed.

2. **Revised the terms of investment in Swaccha Eco Solutions Private Limited (SESPL):** The Board has approved to revise the terms of investment proposed to be made in SESPL by subscribing to 85,200 equity shares at a price of ₹250/- per share, aggregating to a total investment of ₹2,13,00,000/- (Rupees Two Crore Thirteen Lakhs Only) representing 46% of the paid-up capital, thereby making SESPL an associate of the Company.

The detailed disclosure as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023 and such other circulars as applicable, in respect of Sl. No. 2 is enclosed as Annexure I.

The Meeting commenced at 11:35 a.m. and concluded at 11:55 a.m.

This is for your information and records.

Thank you,
For **Mukka Proteins Limited**

MEHABOOBSAB MAHMADGOUS CHALYAL
Digitally signed by MEHABOOBSAB MAHMADGOUS CHALYAL
Date: 2026.11.07 12:25:18 +05'30'

Mehaboobsab Mahmadgous Chalyal
Company Secretary & Compliance Officer
Membership No.: A67502

Encl: as above.

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Mukka Proteins Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Mukka Proteins Limited** ("the Parent"), its subsidiaries (the Parent and its subsidiaries together referred to as "**the Group**") and Group's share of the net profit/loss after tax and total comprehensive income/loss of its joint ventures, for the quarter and half year ended September 30, 2026 (`the Statement') attached herein, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

SHAH & TAPARIA ★ CHARTERED ACCOUNTANTS ★ MUMBAI FRN NO. 109463W

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Mukka Proteins Limited	Parent Company
Haris Marine Products Private Limited	Wholly Owned Subsidiary Company (Domestic)
Atlantic Marine Products Private Limited	Subsidiary Company (Domestic)
Ocean Aquatic Proteins LLC	Subsidiary Company (Foreign)
Ento Proteins Private Limited	Wholly Owned Subsidiary Company (Domestic)
Fabbco Bio Cycle and Bio Protein Technology Private Limited	Subsidiary Company (Domestic)
Ocean Proteins Private Limited	Subsidiary Company (Domestic)
United Gulf Fishery Products LLC	Subsidiary Company (Foreign)
Mukka Frozen Impex	Subsidiary Entity (Domestic)
MPL HRC Eco Solution LLP	Subsidiary Entity (Domestic)
Delta Marine Products	Subsidiary Entity (Domestic)
Ullal Fish Meal and Oil Company	Joint Venture
GSM Marine Export	Joint Venture
Progress Frozen and Fish Sterilization	Joint Venture
Pacific Marine Products	Joint Venture
Mangalore Fishmeal and Oil Company	Joint Venture – Indirect

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in

SHAH & TAPARIA * CHARTERED ACCOUNTANTS * MUMBAI FRN NO. 109463W

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information/ financial results of ten subsidiaries included in the Statement, whose interim financial information/ financial results reflect total assets of Rs. 4568.87 million as at September 30, 2026, total revenues of Rs. 1,859.71 and Rs. 3371.17 million, total net profit after tax of Rs. 78.42 million and Rs.70.61 million and total comprehensive income of Rs. 76.70 and Rs. 64.55 million for the quarter and half year ended September 30, 2026 respectively and net cashflow of Rs. 107.39 million for the half year ended September 30, 2026 as considered in the Statement which have been reviewed by other auditors, whose reports has been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Further, we did not review the interim financial information/ financial results of five joint ventures included in the Statement, whose interim financial information/ financial results reflect share of Loss amounting to Rs. 11.91 million and Rs.21.42 million and Total Comprehensive Loss amounting to Rs. 11.91 million and Rs. 21.42 million for the quarter and half year ended September 30, 2026 respectively as considered in the statement which have been reviewed by other auditors, whose reports have been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of this matter.

For SHAH & TAPARIA
Chartered Accountants
FRN: 109463W

SHAH & TAPARIA * MUMBAI FRN NO. 109463W * CHARTERED ACCOUNTANTS

Bharat Joshi
Partner
M. No.: 130863
UDIN: 26130863CXJUML3855
Date: November 07, 2026
Place: Mumbai

MUKKA PROTEINS LIMITED

CIN: L10207KA2010PLC055771

STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMEBR 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Sr. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Septemeber 30, 2026	June 30, 2026	Septemeber 30, 2025	Septemeber 30, 2026	Septemeber 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Revenue from Operations**						
	Revenue from operations	4,952.82	4,748.04	2,360.81	9,700.86	4,009.62	14,035.15
	Other operating income	135.89	148.50	85.01	284.39	143.93	459.38
	Total Revenue from operations	**5,088.70**	**4,896.54**	**2,445.81**	**9,985.25**	**4,153.55**	**14,494.53**
2	Other income	90.38	15.92	59.99	106.30	85.54	286.81
3	**Total income**	**5,179.08**	**4,912.47**	**2,505.81**	**10,091.55**	**4,239.09**	**14,781.35**
4	**Expenses**						
	Cost of Material Consumed	5,207.15	3,919.82	2,804.52	9,126.97	4,732.98	14,307.25
	Changes in inventories of finished goods, stock in trade and work in progress	(1014.08)	(101.27)	(917.75)	(1115.35)	(1552.96)	(2613.95)
	Employee benefits expenses	123.00	163.35	89.41	286.34	168.30	407.75
	Finance costs	171.44	164.52	128.24	335.96	238.65	535.96
	Depreciation and amortisation expenses	55.99	47.97	41.75	103.96	74.37	165.92
	Other expenses	349.93	434.84	262.40	784.76	452.45	1,247.67
	Total expenses	**4,893.42**	**4,629.22**	**2,408.56**	**9,522.64**	**4,113.79**	**14,050.60**
5	**Profit before exceptional item, Share of Net Profit / (loss) of Associates and Joint Ventures and tax (3-4)**	**285.66**	**283.25**	**97.24**	**568.91**	**125.30**	**730.75**
6	**Exceptional items**	-	-	-	-	-	-
7	**Share of Net Profit / (loss) of Associates and Joint Ventures**	(11.91)	(9.51)	(4.46)	(21.42)	(8.93)	20.69
8	**Profit before tax (5-6+7)**	**273.75**	**273.74**	**92.78**	**547.49**	**116.37**	**751.44**
9	**Total tax expenses**						
	Current Tax	51.05	61.92	23.22	112.96	31.26	189.82
	Deferred Tax	45.40	25.48	0.93	70.89	0.59	(17.92)
	Earlier years	0.02	-	(0.21)	0.02	(0.21)	8.67
10	**Profit after tax (8-9)**	**177.27**	**186.34**	**68.84**	**363.61**	**84.73**	**570.86**
11	**Other Comprehensive Income**						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the net defined benefit plans	**0.83**	**5.29**	**1.00**	**6.12**	**1.21**	**5.19**
	Items that will be reclassified subsequently to profit or loss -						
	Exchange differences on translation of foreign operations	3.57	4.92	(7.93)	8.49	(8.67)	(11.31)
	Total other comprehensive income	**4.40**	**10.21**	**(6.93)**	**14.61**	**(7.46)**	**(6.12)**
12	**Total comprehensive income (10+11)**	**181.68**	**196.55**	**61.91**	**378.23**	**77.27**	**564.73**
	Profit for the year attributable to:						
	Shareholders of the Company	159.86	188.88	58.77	348.73	73.94	520.58
	Non-controlling interests	17.42	(2.53)	10.07	14.88	10.79	50.28
	Other comprehensive income for the year attributable to:						
	Shareholders of the Company	3.05	8.16	(4.00)	11.21	(4.25)	(1.94)
	Non-controlling interests	1.35	2.04	(2.94)	3.40	(3.21)	(4.19)
13	**Paid-up equity share capital (Face Value of the share Re. 1/- each) ***	300.00	300.00	300.00	300.00	300.00	300.00
14	Other equity	-	-	-	-	-	4,690.86
15	**Earnings per share * (Face Value Rs. 1 /- per share)**						
	(a) Basic	0.53	0.63	0.20	1.16	0.25	1.74
	(b) Diluted	0.53	0.63	0.20	1.16	0.25	1.74

*** Basic & Diluted EPS for all periods , except year ended March 31, 2026 , are not annualised.*

See accompanying notes to the financial results

MUKKA PROTEINS LIMITED Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
UN-AUDITED CONSOLIDATED BALANCE SHEET AS AT
SEPTEMEBER 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Particulars	As At	
	September 30, 2026	March 31, 2026
	Rs. In millions	Rs. In millions
ASSETS		
Non-Current assets		
Property, Plant and Equipment	1951.11	1639.21
Capital Work in Progress	225.23	304.73
Right-of-use Assets	127.21	143.49
Intangible Assets	1.29	1.85
Intangible Assets under development	1.65	1.65
Goodwill on Consolidation	140.52	140.52
Investment Property	11.99	12.19
Financial Assets		
Investment	552.19	558.35
Loans	2.37	1.37
Other Financial Asset	199.25	208.63
Income Tax Assets	33.74	59.29
Other non-current assets	77.89	247.97
Deferred tax Assets	11.05	3.74
Total Non-Current Assets	**3,335.49**	**3,322.98**
Current assets		
Inventories	9683.89	8565.53
Financial Assets		
Trade Receivables	3061.13	1818.34
Cash and Cash Equivalents	235.32	128.81
Other bank balances	480.02	475.48
Loans	21.97	105.15
Other Financial Assets	244.84	170.49
Other Current Assets	1539.86	1624.49
Total Current Assets	**15,267.03**	**12,888.29**
Total Assets	**18,602.51**	**16,211.27**
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	300.00	300.00
Other Equity	5080.15	4690.86
Non Controlling Interest	(98.34)	296.88
Total Equity	**5,281.81**	**5,287.75**
LIABILITIES		
Non-Current Liabilities		
Financial Liabilities		
Borrowings	1157.07	321.01
Lease Liabilities	77.20	87.92
Other Financial Liabilities	-	-
Provisions	21.10	23.77
Deferred Tax Liabilities (Net)	78.51	-
Other Non-Current Liabilities	1.34	1.53
Total Non-Current Liabilities	**1,335.22**	**434.24**
Current Liabilities		
Financial Liabilities		
Borrowings	7244.77	7356.69
Lease Liabilities	24.19	27.26
Trade Payables		
'- Due To Micro & Small Enterprises	1610.89	811.71
'- Due To other than Micro & Small Enterprises	1938.58	1594.02
Other Financial Liabilities	50.21	53.37
Other Current Liabilities	936.49	415.44
Provisions	19.56	17.27
Income Tax Liabilities	160.80	213.53
Total Current Liabilities	**11,985.49**	**10,489.29**
Total Equity and Liabilities	**18,602.51**	**16,211.27**

MUKKA PROTEINS LIMITED Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771

STATEMENT OF UN-AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Particulars	Half Year Ended 30th September 2026	Half Year Ended 30th September 2025
	Rs. In millions	Rs. In millions
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax	547.49	116.37
Adjustment for :		
Depreciation / Amortization	103.96	74.37
Interest Expenses	330.11	149.73
Interest Expenses on Lease Liability & Deposits	5.85	3.36
Interest on Capital & Remuneration from partnership firm	(12.65)	(17.65)
Rent Received	(2.17)	(2.18)
Deferred Subsidy	(0.19)	(0.10)
Interest Income	(19.21)	(13.73)
(Profit)/ Loss on Sale of Fixed Assets	(0.54)	(0.41)
Share of Profit/Loss of Associate and Joint Venture	21.42	(8.93)
	426.58	**184.47**
Operating profit before working capital changes	**974.07**	**300.84**
Adjustment for :		
Inventories	(1118.36)	(1581.94)
Trade and Other Receivables	(1145.48)	455.55
Trade Payables	1143.74	(74.95)
Other Current / Non Current Liabilities	529.36	56.20
Provisions	5.74	2.56
Other Financial liabilities	(3.16)	7.41
	(588.17)	**(1135.17)**
Net Cash Generated from Operating activity	**385.90**	**(834.33)**
Income Tax Paid	(139.85)	(17.51)
Net Cash from Operating Activities	246.05	(851.84)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets / capital works-in-progress	(320.88)	(392.88)
Capital Advances	170.07	35.59
Purchase of Investments in Subsidiaries	0.82	(45.69)
Sale proceeds from FA	2.10	6.26
Interest received	19.21	13.73
Interest on Capital & Remuneration Received from firm	12.65	17.65
Share of Profit/Loss of Associate and Joint Venture	(21.42)	8.93
Rent Received	2.17	2.18
Net (Increase) / Decrease in Investments	5.99	(110.34)
Net Cash used in Investing Activities	**(129.30)**	**(464.58)**
C. CASH FLOW FROM FINANCIAL ACTIVITIES		
Net Procedds from Issue (Net of Share Issue Expenses)	117.50	0.00
Changes in borrowings - Non Current	836.05	57.04
Interest Paid	(330.11)	(149.73)
Changes in borrowings - Current	(111.92)	1464.95
Share in Non Controlling Interest	(413.50)	19.65
Changes in deeply subordinated loan	(88.61)	(33.80)
Repayment of Lease Liabilities	(19.65)	(12.47)
Net Cash from Financial Activities	**(10.24)**	**1,345.64**
INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	**106.51**	**29.22**
Cash and Cash equivalents at the beginning	128.81	30.75
Cash and Cash equivalents at the close	**235.32**	**59.97**

MUKKA PROTEINS LIMITED Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
NOTES TO THE STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMEBR 30, 2026

1 The above statement of Un-Audited consolidated financial results for the Quarter & Half Year Ended Septemeber30, 2026 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **November 07, 2026**. The Statutory auditors have carried out an review of the consolidated financial results for the Quarter & Half Year Ended September 30, 2026.

2 The Un-Audited Consolidated Financial Results of the company are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.

3 The figures for the quarter ended September 30, 2026 are balancing figure between the unaudited figures for the period ended September 30, 2026 and published Period to date figures for three months ended June 30, 2026.

The figures for the quarter ended September 30, 2025 are balancing figure between the unaudited figures for the period ended September 30, 2025 and published Period to date figures for three months ended June 30, 2025.

4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as follows :-

(Rupees in Million)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	September 30, 2026	June 30, 2026	Septemeber 30, 2025	Septemeber 30, 2026	Septemeber 30, 2025	March 31, 2026
	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
Within India	817.70	607.36	947.20	1,425.06	1,067.30	2,853.77
Outside India	4,135.12	4,140.68	1,413.60	8,275.80	2,942.32	11,181.38
Total	**4,952.82**	**4,748.04**	**2,360.81**	**9,700.86**	**4,009.62**	**14,035.15**

5 During the quarter under review, the Company allotted 2,00,00,000 (Two Crore) Convertible Warrants on a preferential basis, each carrying a right exercisable by the respective warrant holder to subscribe to one (1) fully paid-up Equity Share of the Company having a face value of ₹1/- (Rupee One only), at an issue price of ₹23.50/- (Rupees Twenty-Three and Fifty Paise only) per Warrant (including a premium of ₹22.50/- per Warrant), aggregating to ₹47,00,00,000/- (Rupees Forty-Seven Crore only).

The Company has received 25% of the issue price, aggregating to ₹11.75 crore, from the warrant holders, with the balance 75% payable at the time of exercise of the conversion option, within 18 months from the date of allotment of the Warrants.

6 The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

For and on behalf of Board of Directors of
Mukka Proteins Limited

MUKKA PROTEINS LIMITED Mangaluru

Kalandan Mohammed Haris
Managing Director and CEO
DIN: 03020471

Date - November 07, 2026
Place: Mangalore

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors,
Mukka Proteins Limited

1. We have reviewed the accompanying statement of unaudited Standalone Financial Results of **Mukka Proteins Limited** ('the Company'), for the quarter and half year ended 30th September 2026, (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") including relevant circulars issued by SEBI from time to time.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (`Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

SHAH & TAPARIA ★ MUMBAI FRN NO. 109463W ★ CHARTERED ACCOUNTANTS

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH & TAPARIA
Chartered Accountants
FRN: 109463W

SHAH & TAPARIA * MUMBAI FRN NO. 109463W * CHARTERED ACCOUNTANTS

Bharat Joshi
Partner
M. No.: 130863
UDIN: 26130863LGJCMF7317

Date: November 07, 2026
Place: Mumbai

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED ON SEPTEMBER 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Sr. No.	Particulars	Quarter Ended			Six Month Ended		Year ended
		September 30,2026 (Un-Audited)	June 30, 2026 (Un-Audited)	September 30,2025 (Un-Audited)	September 30,2026 (Un-Audited)	September 30,2025 (Un-Audited)	March 31, 2026 (Audited)
1	**Revenue from operations**						
	Revenue from operations	3,995.34	3,927.05	2,160.44	7,922.39	3,459.44	11,849.54
	Other operating income	120.09	131.51	62.27	251.59	121.19	442.51
	Total Revenue from operations	**4,115.42**	**4,058.56**	**2,222.71**	**8,173.99**	**3,580.63**	**12,292.05**
2	Other income	89.46	22.99	54.61	112.45	83.04	292.68
3	**Total income (1+2)**	**4,204.88**	**4,081.55**	**2,277.32**	**8,286.43**	**3,663.67**	**12,584.73**
4	**Expenses**						
	Cost of Material Consumed	4,295.52	3,405.13	2,545.41	7,700.65	4,260.84	12,644.41
	Changes in inventories of finished goods, stock in trade and work in progress	(794.99)	(161.42)	(748.12)	(956.42)	(1435.40)	(2535.76)
	Employee benefits expenses	64.80	62.92	60.77	127.72	111.72	245.13
	Finance costs	152.47	146.67	120.83	299.14	224.33	499.10
	Depreciation and amortisation expenses	21.19	19.69	14.97	40.89	28.53	69.39
	Other expenses	282.03	333.57	225.39	615.60	397.60	1,074.66
	Total expenses	**4,021.02**	**3,806.56**	**2,219.25**	**7,827.58**	**3,587.64**	**11,996.94**
5	**Profit before exceptional item and tax (3-4)**	**183.86**	**274.99**	**58.07**	**458.85**	**76.04**	**587.79**
6	**Exceptional items**	-	-	-	-	-	-
7	**Profit before tax (5-6)**	**183.86**	**274.99**	**58.07**	**458.85**	**76.04**	**587.79**
8	**Total tax expenses**						
	Current Tax	32.74	55.89	19.50	88.63	26.59	171.68
	Deferred Tax	44.14	25.02	2.47	69.16	2.00	(16.29)
	Earlier years	-	-	-	-	-	8.28
9	**Profit after tax (7-8)**	**106.99**	**194.07**	**36.10**	**301.06**	**47.45**	**424.12**
10	**Other Comprehensive Income/ (Expenses) (net of tax)**						
	Items that will not be reclassified to profit or loss						
	-Remeasurements of the defined benefit plans	0.83	5.29	1.00	6.12	1.21	5.19
	Other comprehensive income, net of tax	**0.83**	**5.29**	1.00	6.12	1.21	**5.19**
11	**Total Comprehensive Income for the Period (after tax) (9+10)**	**107.82**	**199.36**	**37.10**	**307.18**	**48.66**	**429.32**
12	**Paid-up equity share capital (Face Value of the share Rs. 1/- each)**	300.00	300.00	300.00	300.00	300.00	300.00
13	Other equity	-	-	-	-	-	4,172.98
14	**Earnings per share * (Face Value Rs. 1 /- per share)**						
	(a) Basic	0.36	0.66	0.12	1.02	0.16	1.43
	(b) Diluted	0.36	0.66	0.12	1.02	0.16	1.43

*** Basic & Diluted EPS for all periods , except year ended March 31, 2026 are not annualised.*

See accompanying notes to the financial results

MUKKA PROTEINS LIMITED Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
UN-AUDITED STANDALONE BALANCE SHEET AS AT SEPTEMEBER 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Particulars	As at Septemeber 30, 2026	As at March 31, 2026
	Rs. In millions	Rs. In millions
ASSETS		
Non-Current assets		
Property, Plant and Equipment	806.37	751.77
Capital Work in Progress	47.28	3.70
Right-of-use Assets	108.45	117.61
Intangible Assets	1.29	1.63
Intangible Assets under development	1.65	1.65
Investment Property	11.99	12.19
Financial Assets		
Investment	819.64	710.34
Other Financial Asset	185.19	184.70
Income Tax Assets	19.12	54.89
Other non-current assets	77.89	242.97
Total Non-Current Assets	**2,078.86**	**2,081.44**
Current assets		
Inventories	8,697.76	7,741.35
Financial Assets		
Trade Receivables	2,287.17	1,738.35
Cash and Cash Equivalents	18.53	19.41
Other bank balances	464.61	461.20
Loans	166.16	135.15
Other Financial Assets	242.40	160.11
Other Current Assets	1,467.40	1,346.89
Total Current Assets	**13,344.04**	**11,602.45**
Total Assets	**15,422.90**	**13,683.89**
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	300.00	300.00
Other Equity	4,597.67	4,172.98
Total Equity	**4,897.67**	**4,472.98**
LIABILITIES		
Non-Current Liabilities		
Financial Liabilities		
Borrowings	840.28	60.74
Lease Liabilities	102.65	109.88
Provisions	21.10	23.77
Deferred Tax Liabilities (Net)	78.36	8.88
Other Non-Current Liabilities	1.34	1.53
Total Non-Current Liabilities	**1,043.73**	**204.81**
Current Liabilities		
Financial Liabilities		
Borrowings	6,539.46	6,639.13
Lease Liabilities	14.29	13.71
Trade Payables		
- Due to Micro & Small Enterprises	1,245.20	697.83
- Due to other than Micro & Small Enterprises	1,393.19	1,381.75
Other Financial Liabilities	36.82	37.25
Other Current Liabilities	126.21	54.90
Provisions	12.21	9.85
Income Tax Liabilities	114.12	171.68
Total Current Liabilities	**9,481.50**	**9,006.10**
Total Equity and Liabilities	**15,422.90**	**13,683.89**

MUKKA PROTEINS LIMITED Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
UN-AUDITED STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON SEPTEMBER 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Particulars	Half Year Ended 30th September 2026	Half Year Ended 30th September 2025
	Rs. In millions	Rs. In millions
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax	458.85	76.04
Adjustment for :		
Depreciation / Amortization	40.89	28.53
Interest Expenses	293.65	137.21
Interest Expenses on Lease Liability & Security Deposits	5.49	1.99
Interest on Capital & Remuneration from partnership firm	(12.65)	(7.74)
Rent Received	(9.69)	(9.07)
Deferred Subsidy	(0.19)	(0.10)
Interest Income	(25.31)	(18.80)
(Profit)/loss on Sale of Fixed Assets	(0.54)	0.00
Gain on Termination of lease contract	-	(0.07)
	291.65	**131.95**
Operating profit before working capital changes	**750.50**	**207.99**
Adjustment for :		
Inventories	(956.42)	(1435.40)
Trade Receivables and Other Assets	(626.95)	373.08
Trade Payables	558.81	-220.47
Other Current & Non Current Liabilities	71.31	(6.45)
Provisions	5.82	0.84
Other Financial liabilities	(0.43)	6.32
Other Non-Current Liabilities	(0.19)	
	(948.05)	**(1282.07)**
Net Cash Generated from Operating activity	**(197.55)**	**(1074.09)**
Income Tax Paid	(110.11)	(20.56)
Net Cash from operating activities	**(307.66)**	**(1094.65)**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets	(87.34)	(43.51)
Investment in Capital Works-in-Progress	(43.58)	(69.04)
Sale proceeds from FA	2.10	0.06
Interest received	25.31	18.80
Investment Property Changes	0.20	-
Interest on Capital & Remuneration Received from Partnership Firm	12.65	7.74
Rent Received	9.69	9.07
Net (Increase) / Decrease in Investments	(109.30)	(167.80)
Net cash used in investing activities	**(190.28)**	**(244.67)**
C. CASH FLOW FROM FINANCIAL ACTIVITIES		
Net Procedds from Issue (Net of Share Issue Expenses)	117.50	-
Changes in borrowings - Non Current	779.54	52.68
Interest Paid	(293.65)	(137.21)
Changes in borrowings - Current	(99.67)	1,429.16
Repayment of Lease Liabilities	(6.65)	(6.78)
Net Cash from financial activities	**497.07**	**1,337.84**
INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	**(0.88)**	**(1.47)**
Cash and Cash equivalents at the beginning	19.41	4.43
Cash and Cash equivalents at the close	**18.53**	**2.95**

MUKKA PROTEINS LIMITED Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
NOTES TO THE STATEMENT OF UN- AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2026

1 The above statement of Un-audited Standalone Financial Results for the Quarter & Half Year ended Septemeber 30, 2026 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **November 07, 2026.** The Statutory auditors have carried out limited review of the standalone financial results for the Quarter ended September 30, 2026.

2 The Un-Audited Standalone Financial Results of the company are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.

3 The figures for the quarter ended September 30, 2026 are balancing figure between the unaudited figures for the period ended September 30, 2026 and published Period to date figures for three months ended June 30, 2026.

The figures for the quarter ended September 30, 2025 are balancing figure between the unaudited figures for the period ended September 30, 2025 and published Period to date figures for three months ended June 30, 2025.

4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as follows :-

(Rupees in Million)

Particulars	Quarter Ended			Half Year Ended		Year ended
	September 30, 2026	June 30, 2026	September 30, 2025	Septemeber 30, 2026	Septemeber 30, 2025	March 31, 2026
	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
Within India	422.09	400.51	913.58	822.60	1,028.30	2,406.66
Outside India	3573.25	3526.55	1246.86	7099.79	2431.14	9,442.88
Total	**3,995.34**	**3,927.05**	**2,160.44**	**7,922.39**	**3,459.44**	**11,849.54**

5 During the quarter under review, the Company allotted 2,00,00,000 (Two Crore) Convertible Warrants on a preferential basis, each carrying a right exercisable by the respective warrant holder to subscribe to one (1) fully paid-up Equity Share of the Company having a face value of ₹1/- (Rupee One only), at an issue price of ₹23.50/- (Rupees Twenty-Three and Fifty Paise only) per Warrant (including a premium of ₹22.50/- per Warrant), aggregating to ₹47,00,00,000/- (Rupees Forty-Seven Crore only).

The Company has received 25% of the issue price, aggregating to ₹11.75 crore, from the warrant holders, with the balance 75% payable at the time of exercise of the conversion option, within 18 months from the date of allotment of the Warrants.

6 The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

For and on behalf of Board of Directors of
Mukka Proteins Limited

Kalandan Mohammed Haris
Managing Director and CEO
DIN: 03020471

MUKKA PROTEINS LIMITED Mangaluru

Date - November 07, 2026
Place: Mangalore

Annexure-1

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	Name of the Target entity: Swaccha Eco Solutions Private Limited ("SESPL") Authorized Capital: Rs. 10,00,000/- Paid up Capital: Rs. 5,00,000/- Turnover (FY 2025-26): Rs. 1,77,61,136 PAT (FY 2025-26): Rs. (75,05,051) Net worth (FY 2025-26): Rs. (2,10,22,476)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Not a related party transaction.
3.	Industry to which the entity being acquired belongs;	Collection, treatment and disposal of all types of waste
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed investment is being made as a part of Company's strategic investment plans to expand the Waste Management segment of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	31-03-2027
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Acquisition of 85,200 equity shares of face value of Rs. 10/- each of SESPL at a price of Rs. 250/- per equity share for a total consideration of Rs. 2,13,00,000/-.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Proposed to acquire 85,200 equity shares of face value of Rs.10/- each of SESPL at a price of Rs. 250/- per equity share for a total consideration of Rs. 2,13,00,000/-. Post-acquisition Shareholding will be 46%.

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	SESPL is in the business of Collection, treatment and disposal of all types of waste. Line of Business: Collection, treatment and disposal of all types of waste Date of Incorporation: 12th September 2017 Turnover of last 3 years: As on March 2024: Rs. 1,44,45,028 As on March 2025: Rs. 2,77,64,810 As on March 2026: Rs. 1,77,61,136 Country in which the acquired entity has presence: India

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771